Inflammation in atherosclerosis: new opportunities for drug discovery.
Many lines of evidence indicate that inflammation is the ultimate cause of atherosclerosis; high cholesterol levels cause atherosclerosis through mechanism of inflammation. Drugs designed to address inflammatory aspects of atherosclerosis will likely be more effective than current therapies in treating and preventing coronary artery disease.
Meng
Charles Q
CQ
AtheroGenics, Inc., 8995 Westside Parkway, Alpharetta, Georgia 30004, USA. cmeng@atherogenics.com
D000818:Animals; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D002097:C-Reactive Protein / Q000502:physiology; D015815:Cell Adhesion Molecules / Q000187:drug effects; D018925:Chemokines / Q000502:physiology; D002784:Cholesterol / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology
D015815:Cell Adhesion Molecules; D018925:Chemokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D002784:Cholesterol